30 results about "Methane sulfonate" patented technology

The invention discloses an antibacterial bamboo fiber for traceless underwear and a preparation method of the antibacterial bamboo fiber, and relates to the technical field of textile fibers. When the antibacterial bamboo fiber for the traceless underwear is prepared, bamboo pulp reacts with 3-aminopropyltrimethoxysilane to prepare modified bamboo pulp; the preparation method comprises the following steps: copolymerizing acrylonitrile and dibutyl (allyl) phosphine to prepare pre-modified polyacrylonitrile; enabling the pre-modified polyacrylonitrile to react with pyrimidine-2-yl methyl methanesulfonate, so as to obtain modified polyacrylonitrile; the modified polyacrylonitrile and the modified bamboo pulp are mixed and then subjected to wet spinning, then the mixture is immersed in deionized water, and polyacrylonitrile modified bamboo fibers are prepared; and immersing the polyacrylonitrile modified bamboo fiber into a silver plating solution to prepare the antibacterial bamboo fiber for the traceless underwear. The antibacterial bamboo fiber for traceless underwear prepared by the invention has good antibacterial, flame-retardant and moisture-absorbing properties.

The present invention relates to the field of medical intermediates, and provides a preparation method for a key intermediate tert-butyl (3aR,5S,6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate mesylate of a JAK kinase inhibitor. The method comprises: reacting tert-butyl cis-5-oxohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate as a raw material with a methylamine equivalent to obtain intermediate A; and then carrying out a reduction reaction in metallic sodium and isopropanol to obtain a crude product, adding L-DBTA to form a salt, removing isomers, and then carrying out re-liberation and salt formation with methanesulfonic acid to obtain a purified product. The method significantly reduces reaction steps, reduces raw material costs, has a simple and reliable process, and is easy for industrial production.

An Aspergillus niger mutant strain designated MTCC 25759 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg / mL for 30 to 60 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The mutant strain exhibits genetic modifications at 47 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance to acidic fermentation conditions. The mutant strain achieves gluconic acid production of 198.836 g / L representing a 66% improvement over the parent strain's 119.776 g / L yield, and citric acid production reaching 0.415 g / L with consistent late-phase productivity. The enhanced production capabilities provide economic advantages through improved substrate conversion rates, reduced raw material costs, and increased production capacity within existing fermentation infrastructure while maintaining the Generally Regarded As Safe (GRAS) status for commercial applications.

The present invention relates to a pharmaceutically acceptable salt of a sphingosine-1-phosphate receptor agonist and a crystalline form thereof, and more specifically, to a potassium salt or methanesulfonate of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid of formula 1, and a crystalline form thereof.

The present invention refers to three new polymorphic forms of phentolamine mesylate and to the processes for their production.

The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg / mL±50 mg / mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.

The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

The invention discloses a method for innocent treatment of household garbage incineration fly ash, which comprises the following steps: (1) fly ash pretreatment: taking household garbage incineration fly ash as a raw material, and drying to obtain a pretreated fly ash raw material; (2) preparation of a methanesulfonic acid-iron methanesulfonate extracting solution: firstly adding lead oxide into a methanesulfonic acid solution to form lead methanesulfonate, then adding ferric sulfate to mutually convert soluble salts into iron methanesulfonate and precipitate lead sulfate, and taking the light pink supernatant as an extraction stock solution which is a methanesulfonic acid-iron methanesulfonate stock solution; and (3) metal extraction and dechlorination are conducted, specifically, the fly ash raw material and the methanesulfonic acid-iron methanoate solution are mixed to react, and after the reaction is completed, a leaching solution is obtained through filtering. According to the invention, the use of chemical agents is effectively reduced, and the energy consumption is low. And the obtained leachate is subjected to subsequent treatment, so that a methanesulfonic acid-iron methanoate solution can be reused for metal leaching and dechlorination steps, and the whole method is more green and feasible.

This application discloses a crystal form of an acid addition salt of an ATR inhibitor, its preparation method, and its uses. The crystal form of the acid addition salt includes at least one of the hydrogen sulfate and methanesulfonate crystal forms of the compound shown in formula (I). The crystal form of the acid addition salt of this application has advantages such as strong preparation stability, high solubility, and low hygroscopicity, making it more suitable for formulation preparation. (I)

The invention relates to a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine, in particular to a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine, and a salt derivative of (R)-6-(5-fluoropyridin-2-yl)-8-methoxy-N-(1-(5-methyl-1, 2, 4-oxadiazol-3-yl) ethyl) quinazoline-4-amine. The present invention relates to mesylate and ethanesulfonate salts of 2, 4-oxadiazol-3-yl) ethyl) quinazolin-4-amine, pharmaceutical compositions containing such salts, and therapeutic uses thereof. The salts of the invention are useful in the treatment of diseases or conditions associated with respiratory diseases, in particular chronic cough.

Provided are a free base or pharmaceutically acceptable salt of a pyrazoloquinazoline compound of formula (I), which can be used as a PLK1 inhibitor, optionally in a crystalline form, and a solvate or hydrate thereof, wherein the pharmaceutically acceptable salt comprises a hydrochloride, sulfate, phosphate, maleate, fumarate, L-tartrate, citrate, L-aspartate, hippurate, L-glutamate, L-malate, adipate, glutarate, p-toluenesulfonate, and methanesulfonate of the pyrazoloquinazoline compound of formula (I), and also provided is a pharmaceutical composition comprising same, and a use thereof in the treatment of diseases and conditions caused by dysregulated activity of PLK1 and / or diseases and conditions related to PLK1, such as cancer.

The present disclosure provides a novel salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide and a method for preparing the same. The mesylate salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide, which may be prepared using methanesulfonic acid and, without wishing to be bound by theory, can exhibit reduced hygroscopicity and improved physicochemical stability and solubility. In some aspects, the present disclosure provides a pharmaceutical composition for preventing or treating a sodium channel blocker-related disease, comprising the mesylate salt of 5-chloro-2-fluoro-4-((4-fluoro-2-(methyl(2-(methylamino)ethyl)amino)phenyl)amino)-N-(thiazol-4-yl)benzenesulfonamide.

Disclosed are a salt (mesylate salt) of methanesulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of a rucotinib phosphate intermediate 3-cyclopentyl acrylonitrile. The method comprises the following steps: taking chlorocyclopentane as an initial raw material, reacting with magnesium chips to prepare a Grignard reagent cyclopentylmagnesium chloride, reacting with N, N-dimethylformamide to generate cyclopentylformaldehyde, carrying out addition reaction with sodium hydrogen sulfite to generate alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt, and carrying out reaction with sodium hydrogen sulfite to obtain the cyclopentylmagnesium chloride-alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt-alpha-hydroxyl-cyclohexane methanesulfonic acid sodium salt. And reacting the 3-cyclopentyl acrylonitrile with diethyl cyanomethylphosphonate to generate the 3-cyclopentyl acrylonitrile. The method has the advantages of simple synthetic route, convenience in operation, low cost, small amount of three wastes, environment friendliness and high product purity, and is more suitable for industrial mass production.

The present invention belongs to the field of pharmaceutical intermediates. Provided in the present invention is a scale-up preparation method for tert-butyl (3aR,5S,6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate methanesulfonate. The method comprises: subjecting tert-butyl cis-5-oxohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylate and a reducing agent, which serve as raw materials, to a reaction in an organic solvent to obtain intermediate 1; subsequently, subjecting the intermediate to a Mitsunobu reaction with CH 3NHCbz to obtain intermediate 2; and finally, performing palladium-on-carbon catalyzed hydrogenation, followed by salt formation with methanesulfonic acid to obtain the product tert-butyl (3aR,5S,6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate methanesulfonate. The method reduces raw material costs, has a simple and reliable process with easy industrialization, and provides a new reaction route for the synthesis of tert-butyl (3aR,5S,6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate methanesulfonate.

The invention relates to a compound of formula I or II (I), (II), A- being a counteranion selected from the following ions: chloride, bromide, iodide, acetate, methane sulfonate, benzene sulfonate, camphosulfonate, tartrate, dibenzoate, ascorbate, fumarate, citrate, phosphate, salicylate, oxalate, bromohydrate, tosylate, and X being a 3-carbon alkyl group. The invention also relates to this compound for its use as a medicinal product, particularly in the treatment of neuropsychiatric disorders. Figure to be published with the abstract: Figure 1

The invention discloses a dispersing agent based on sensitive dye application, and belongs to the technical field of dispersing agents. The dispersing agent is prepared from the following raw materials in parts by mass: 55 to 65 parts of sodium lignin sulfonate, 4 to 7 parts of sodium taurocholate and 6 to 10 parts of 1-dodecyl-3-methylimidazole mesylate. The preparation method comprises the following steps: carrying out sedimentation, flocculation, filtration and membrane concentration on the papermaking black liquid, introducing sulfur dioxide gas for treatment, and separating out lignin; the method comprises the following steps: pre-oxidizing lignin, and then carrying out sulfonation and methylation reactions to obtain sodium lignin sulfonate; the preparation method comprises the following steps: mixing sodium lignin sulfonate, deionized water, sodium taurocholate and 1-dodecyl-3-methylimidazole mesylate to form a composite dispersion system, and carrying out spray drying to obtain the dispersing agent based on sensitive dye application. The dispersing agent has high thermal stability and high dispersity, can be applied to fabric sensitive dye dyeing, and effectively improves the color fastness of dyed fabrics.

The invention relates to a compound of formula I or II (I), (II), A- being a counteranion selected from the following ions: chloride, bromide, iodide, acetate, methane sulfonate, benzene sulfonate, camphosulfonate, tartrate, dibenzoate, ascorbate, fumarate, citrate, phosphate, salicylate, oxalate, bromohydrate, tosylate, and X being a 3-carbon alkyl group. The invention also relates to this compound for its use as a medicinal product, particularly in the treatment of neuropsychiatric disorders. Figure to be published with the abstract: Figure 1

The application discloses a kind of traceless underwear antibacterial bamboo fiber and preparation method thereof, it is related to textile fiber technical field.The application is prepared when traceless underwear antibacterial bamboo fiber is prepared, and 3-amino propyl trimethoxysilane is reacted with bamboo pulp to obtain modified bamboo pulp;Acrylonitrile is copolymerized with dibutyl (allyl) phosphine to obtain pre-modified polyacrylonitrile;Pre-modified polyacrylonitrile is reacted with pyrimidine-2-yl methyl methane sulfonate to obtain modified polyacrylonitrile;Modified polyacrylonitrile is mixed with modified bamboo pulp and then wet spinning, and then immersed in deionized water to obtain polyacrylonitrile modified bamboo fiber;Traceless underwear antibacterial bamboo fiber is prepared by immersing polyacrylonitrile modified bamboo fiber in silver plating solution.The traceless underwear antibacterial bamboo fiber prepared by the application has good antibacterial, flame-retardant and moisture-absorbing properties.

The invention discloses a preparation method of gepodamycin mesylate, which comprises the following steps: step a, reacting a compound SM1 with a compound SM2 to obtain a compound 1, and then removing a protecting group from the compound 1 to obtain a compound 2; or reacting the compound SM1 with a compound SM5 to obtain a compound 2; b, carrying out substitution reaction on the compound 2 and a compound SM3 to obtain a compound 3; and step c, salifying the compound 3 and methanesulfonic acid to obtain the gepodamycin mesylate. The preparation method disclosed by the invention is mild in reaction condition, short in reaction route, simple and convenient to operate, suitable for industrial production, low in material cost and high in yield, does not need to use a highly toxic reagent or a dangerous reagent, and greatly reduces the production cost of the gepodamycin mesylate.

The present application relates to a series of compounds methane sulfonate and methane sulfonate nonlinear optical crystal and preparation method and use, the molecular general formula of the series of compounds is A3[CH3SO3]X2, wherein A=NH4, K, Rb, Cs, X=[NO3], Cl, Br, the molecular weight is 220.12-617.82, top seed method is prepared, orthorhombic system, space group Cmc 21 (No.36), the cell parameter is a=12.0014 (6) -12.5667 (2) Å, b=8.0324 (11) -8.4995 (1) Å, c=10.8823 (4) -11.3622 (15) Å, α =90, β =90, γ =90, Z =4, V=1048.4 (3) -1212.8 (2) Å 3 The series of compounds methane sulfonate nonlinear optical crystal obtained by the method has the advantages of wide light transmission waveband, stable physical and chemical properties, moderate mechanical hardness, not easy to break, easy to cut, polish processing and preservation and the like.

Disclosed in the present invention are a triazolo ring compound methanesulfonate crystal form, a preparation method therefor and a use thereof. Specifically, disclosed are a crystal form of a compound methanesulfonate of formula (I), and a preparation method therefor and a use thereof, wherein the methanesulfonate crystal form is selected from crystal forms A-I; and disclosed are a preparation method for the crystal form and a pharmaceutical composition containing the crystal form. The preparation method of the present invention is simple and easy to implement and suitable for industrial large-scale production; the crystal forms A-I of the compound methanesulfonate of formula (I) prepared have good solubility and stability, thereby facilitating the preparation and storage of pharmaceutical preparations.

The invention relates to a preparation method of pyridostigmine bromide. The preparation method comprises the following steps: reacting 3-(N, N-dimethyl carbamoyloxy) pyridine (formula II) with a methylation reagent methyl methanesulfonate or methyl p-toluenesulfonate to generate 3-[(dimethyl carbamoyloxy)-1-methylpyridinium mesylate or 3-[(dimethyl carbamoyloxy)-1-methylpyridinium p-toluenesulfonate (formula III); and dissolving the formula III in acetonitrile, adding lithium bromide for reaction, filtering to remove the precipitated lithium salt, concentrating the filtrate, and purifying in any form to obtain pyridostigmine bromide. According to the preparation method of pyridostigmine bromide provided by the invention, the use of a high-toxicity ozone consuming substance-bromomethane is avoided, and the method is simple in process operation, safe and environment-friendly, low in requirements on plants and equipment, high in product purity and low in production cost, and has obvious industrialization and commercialization advantages. .

The present application relates to the technical field of oilfield chemistry, and is a kind of amphiprotic polymer and its preparation method and application, the former is obtained by copolymerization of anionic monomer, first cationic monomer, second cationic monomer and crosslinking monomer;The anionic monomer is one or more of sodium vinyl sulfonate, sodium allyl sulfonate, sodium methacrylate sulfonate, sodium p-styrene sulfonate, (4-vinyl) phenyl methane sulfonate sodium, 3-allyloxy-2-hydroxy-1-propane sulfonate sodium or 2-acrylamide-2-methyl propane sulfonate sodium;The first cationic monomer is N-allyl-N, N-dimethyl cyclohexyl ammonium chloride;The second cationic monomer is allyl tributyl phosphonium chloride;The crosslinking monomer is N, N'-methylene bisacrylamide. The amphiprotic polymer has high charge density, outstanding performance as clay stabilizer, high anti-swelling rate, excellent water washing resistance, does not harm the sand carrying capacity of fracturing fluid, and is suitable for fracturing operation in high temperature and even super high temperature reservoir.

The application discloses a perovskite solar cell based on trimethylsilyl methanesulfonate modification and a preparation method thereof. The cell comprises an anode substrate, an electron transport layer, a buried bottom interface modification layer, a perovskite light absorption layer, a top interface modification layer, a hole transport layer and a cathode layer. The electron transport layer is SnO2 modified by ammonium tartrate (AT) and nitric acid (HNO3), and the perovskite light absorption layer is CsPbI2Br. Trimethylsilyl methanesulfonate (TMSEs) is used as the buried bottom interface modification layer to modify the interface between the SnO2 electron transport layer and the CsPbI2Br perovskite light absorption layer, to construct a molecular bridge on the interface, to passivate the defects of the SnO2 / CsPbI2Br interface, to inhibit the non-radiative recombination of the interface, and to improve the room-temperature black-phase stability of the CsPbI2Br perovskite film, thereby improving the performance of the perovskite solar cell device. The method has low cost, is simple and easy to operate, is suitable for the preparation of large-scale perovskite solar cells, and has important research and application values.

This invention discloses a method for synthesizing a polyalkyl polysaccharide compound that is a substitute for reactive printing urea. The steps are as follows: (1) Acrylamide ethylenediamine, sodium 4-vinylbenzene methane sulfonate and pure water are thoroughly mixed and the pH of the solution is adjusted; (2) Initiator and solution from step (1) are added dropwise to a flask; (3) Polysaccharide is added to the flask, epichlorohydrin is added, an alkaline aqueous solution is added dropwise, and the pH is adjusted to neutral with acid; (4) The product from step (1) is placed in a flask, a nucleophilic reaction catalyst is added, and the aqueous solution from step (3) is added dropwise to obtain the target product, polyalkyl polysaccharide compound. This invention uses the above-mentioned method for synthesizing a polyalkyl polysaccharide compound that is a substitute for reactive printing urea. The synthesized polyalkyl polysaccharide compound can effectively improve the three functions of reactive dyes in sizing: water retention and moisture absorption, dispersion and compressibility, and fiber expansion. It can also effectively promote the color development of reactive dyes during evaporation and effectively reduce ammonia nitrogen emissions.

Compounds of structure (I) are described wherein, R1, R2, R1a and R2a are independently selected from H, nitro, cyano, and an alkylsulfonyl, wherein at least two of R1, R2, R1a and R2a are independently selected from nitro, cyano, and an alkylsulfonyl, and X− is not a halide, tosylate, trifluoromethylsulfonate, tetrafluoroborate, an aryl-substituted borates, hexafluorophosphate, hexafluoroarsenate, acetate, trifluoroacetate, methane sulfonate, C-2 to C-20 linear unsubstituted alkyl sulfonates, naphthalenesulfonate, and camphorsulfonate. Also described are EUV negative and positive chemically amplified photoresist compostions containing said compound and the process of using these photoresist to pattern a substrate.

The present invention relates to the field of pharmaceuticals, and in particular, to a salt form of a pyridazine derivative, a crystal form, a method for preparing same, and use thereof. The present invention provides a salt form of a compound of formula I, and particularly relates to a hydrochloride salt, a hydrobromide salt, a sulfate salt, a phosphate salt, an oxalate salt, a citrate salt, a malate salt, a maleate salt, a fumarate salt, a succinate salt, a malonate salt, a methanesulfonate salt, a benzenesulfonate salt, and a p-toluenesulfonate salt. The present invention further provides an amorphous form and a crystal form of the hydrochloride salt, and particularly relates to crystal form A and crystal form B. The present invention further provides a method for preparing the salt form and the crystal form, and use thereof. The salt form of the compound of formula I and the crystal form of the present invention have significant SOS1 inhibitory activity and a significant anti-tumor cell proliferation effect, have advantageous pharmaceutical properties such as high solubility, good stability, and excellent pharmacokinetics, and are thus suitable for pharmaceutical use.

The application provides a preparation method of a JAK kinase inhibitor key intermediate (3aR, 5S, 6aS)-5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-formic acid tert-butyl ester methanesulfonic acid salt, and belongs to the field of pharmaceutical intermediates. Cis-5-oxohexahydrocyclopenta[C]pyrrole-2(1H)-carboxylic acid tert-butyl ester is used as raw material to react with a methylamine equivalent to obtain an intermediate A; then a reduction reaction occurs in sodium metal and isopropyl alcohol to obtain a crude product, L-DBTA is added to form a salt, isomer is removed, and after re-ionization and methanesulfonic acid salt formation, a pure product is obtained. The method greatly shortens the reaction steps, reduces the raw material cost, and is simple and reliable in process, and easy to industrialized production.